Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Gilead Sciences, Inc.. Director active across 5 companies, notably Arcus Biosciences, Inc.. Aggregated, 11 disclosures have been published. Breakdown: 9 buys · 0 sell. Total volume traded: €358.8m. Activity tracked since 27 June 2023. The latest transaction was filed on 26 May 2026 (Attribution). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Gilead Sciences, Inc.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2,930,870 shares@ US$3.75100.0% of flowCommon StockSEC:0001062993-23-014111:0
Canonical exit: 25 Sept 2023 (T+90)
11 of 11 declarations
About Gilead Sciences, Inc.
GILEAD SCIENCES, INC. is a declarant with no primary role indicated. It has 11 filings in total, and in the sampled recent filings the transactions are mainly acquisitions, with buy or other transactions in Arcus Biosciences, Inc., Assembly Biosciences, INC. and Allovir, Inc. between 2023-06-28 and 2026-05-27.